Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 4
1987 7
1988 11
1989 17
1990 44
1991 67
1992 71
1993 100
1994 105
1995 131
1996 157
1997 134
1998 152
1999 154
2000 175
2001 237
2002 237
2003 236
2004 255
2005 303
2006 268
2007 226
2008 261
2009 190
2010 208
2011 194
2012 180
2013 178
2014 178
2015 150
2016 174
2017 136
2018 126
2019 107
2020 120
2021 103
Text availability
Article attribute
Article type
Publication date

Search Results

5,013 results
Results by year
Filters applied: . Clear all
Page 1
Statin therapy increases lipoprotein(a) levels.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Tsimikas S, et al. Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. Eur Heart J. 2020. PMID: 31111151
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day, rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. ...-statin pooled analysis, the ratio of geometric means (95% CI) for ato …
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin …
Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.
Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D'Alton M, Hankins G; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Costantine MM, et al. Am J Obstet Gynecol. 2016 Jun;214(6):720.e1-720.e17. doi: 10.1016/j.ajog.2015.12.038. Epub 2015 Dec 23. Am J Obstet Gynecol. 2016. PMID: 26723196 Free PMC article. Clinical Trial.
Women between 12(0/7) and 16(6/7) weeks' gestation were assigned to daily pravastatin 10 mg or placebo orally until delivery. Primary outcomes were maternal-fetal safety and pharmacokinetic parameters of pravastatin during pregnancy. ...Pravastatin use was as …
Women between 12(0/7) and 16(6/7) weeks' gestation were assigned to daily pravastatin 10 mg or placebo orally until delivery. Primary …
Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review.
Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Esteve-Valverde E, et al. Obstet Gynecol Surv. 2018 Jan;73(1):40-55. doi: 10.1097/OGX.0000000000000522. Obstet Gynecol Surv. 2018. PMID: 29368790 Review.
IMPORTANCE: We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia. OBJECTIVE: The aim of this study was to examine whether pravastatin is a useful and safe alternative for treating preeclampsia during pregnan …
IMPORTANCE: We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia. OBJECTIV …
Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.
Wagner JB, Ruggiero M, Leeder JS, Hagenbuch B. Wagner JB, et al. Drug Metab Dispos. 2020 Nov;48(11):1192-1198. doi: 10.1124/dmd.120.000122. Epub 2020 Sep 5. Drug Metab Dispos. 2020. PMID: 32892153 Free PMC article.
Pravastatin acid (PVA) can be isomerized to its inactive metabolite 3'alpha-iso-pravastatin acid (3alphaPVA) under acidic pH conditions. ...This suggests that a lower concentration of 3'alpha-iso-pravastatin is needed to disrupt OATP1B1-mediated pravastati …
Pravastatin acid (PVA) can be isomerized to its inactive metabolite 3'alpha-iso-pravastatin acid (3alphaPVA) under acidic pH c …
Pravastatin sodium.
Al-Badr AA, Mostafa GA. Al-Badr AA, et al. Profiles Drug Subst Excip Relat Methodol. 2014;39:433-513. doi: 10.1016/B978-0-12-800173-8.00008-8. Profiles Drug Subst Excip Relat Methodol. 2014. PMID: 24794911 Review.
Pravastatin sodium is an [HMG-CoA] reductase inhibitor and is a lipid-regulating drug. ...The chapter also contains the pharmacokinetics, metabolism, stability, and articles that reviewed pravastatin sodium manufacturing, characterization, and analysis. One hundred …
Pravastatin sodium is an [HMG-CoA] reductase inhibitor and is a lipid-regulating drug. ...The chapter also contains the pharmacokinet …
A prospective study of pravastatin in the elderly at risk: new hope for older persons.
Shepherd J. Shepherd J. Am J Geriatr Cardiol. 2004 May-Jun;13(3 Suppl 1):17-24. Am J Geriatr Cardiol. 2004. PMID: 15133425 Review.
Although transient ischemic attacks fell by 25% (p=0.05) with pravastatin, there were no significant reductions in stroke or improvements in cognitive function. These results demonstrate the benefits of pravastatin in primary and, particularly, secondary prevention …
Although transient ischemic attacks fell by 25% (p=0.05) with pravastatin, there were no significant reductions in stroke or improvem …
Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies.
Girardi G. Girardi G. J Reprod Immunol. 2017 Nov;124:15-20. doi: 10.1016/j.jri.2017.09.009. Epub 2017 Sep 29. J Reprod Immunol. 2017. PMID: 29028516 Review.
In addition, pravastatin is hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. Several pilot studies suggest that pravastatin may be a good option to prevent and treat preeclampsia in women. ...
In addition, pravastatin is hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. Several pilo …
Pravastatin: an evidence-based statin?
del Sol AI, Nanayakkara PW. del Sol AI, et al. Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):821-5. doi: 10.1517/17425255.4.6.821. Expert Opin Drug Metab Toxicol. 2008. PMID: 18611121 Review.
With 40 mg pravastatin daily, total cholesterol can be reduced by 25-34% with a very consistent risk reduction of 24% of death from cardiovascular diseases. ...Therefore, when the expected 25-34% LDL cholesterol lowering would be enough to reach an LDL<2.5 mmol/l, treat …
With 40 mg pravastatin daily, total cholesterol can be reduced by 25-34% with a very consistent risk reduction of 24% of death from c …
Pravastatin for preeclampsia: From animal to human.
Kumasawa K, Iriyama T, Nagamatsu T, Osuga Y, Fujii T. Kumasawa K, et al. J Obstet Gynaecol Res. 2020 Aug;46(8):1255-1262. doi: 10.1111/jog.14295. Epub 2020 Jun 2. J Obstet Gynaecol Res. 2020. PMID: 32485787
Recently, statins have been reported to improve the regeneration of vascular endothelium, and pravastatin has attracted attention as a potential preventative or therapeutic candidate for preeclampsia. Pravastatin has been demonstrated to have preventative effects in …
Recently, statins have been reported to improve the regeneration of vascular endothelium, and pravastatin has attracted attention as …
Pharmacogenomic importance of pravastatin.
Peters B, Maitland-van der Zee AH. Peters B, et al. Pharmacogenomics. 2008 Sep;9(9):1207-10. doi: 10.2217/14622416.9.9.1207. Pharmacogenomics. 2008. PMID: 18781848 Review.
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly prescribed to reduce risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the i …
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly …
5,013 results